In the third quarter, Financial Consulate Inc. initiated a position in Johnson & Johnson by purchasing 3,364 shares valued at approximately $624,000, according to the firm’s latest Form 13F filing with the U.S. Securities and Exchange Commission. This marks the firm’s first reported investment in the healthcare giant, reflecting confidence in J&J’s diversified portfolio across pharmaceuticals, medical devices and consumer health segments. The acquisition represents a strategic allocation given J&J’s stable cash flows and industry-leading research and development outlays, which totaled $10.4 billion through the first nine months of the year.

Virginia Retirement Systems et al. augmented its J&J stake by 12.3% during the third quarter, adding 127,100 shares to bring its total holdings to 1,158,903 shares. At quarter-end, this position was valued at roughly $215 million, making J&J its ninth largest portfolio holding and accounting for 1.4% of its overall assets. The increase underscores the pension fund’s view of J&J as a core long-term holding, supported by a consistent dividend track record and a debt-to-equity ratio of 0.50.

Institutional investors and hedge funds collectively own 69.55% of J&J’s outstanding shares, underlining the company’s appeal to large-scale asset managers. Five research firms have recently raised their target price on J&J, and the consensus rating stands at Moderate Buy with an average price objective of $211.25. J&J maintains a pristine credit profile, including a AAA bond rating from major agencies, reflecting a current ratio of 1.07 and a quick ratio of 0.80, which support ongoing investment in R&D and acquisitions without compromising balance‐sheet strength.

J&J declared a quarterly dividend of $1.30 per share to be paid to shareholders of record on February 24, representing a 2.5% yield based on recent share counts and an annualized payout of $5.20 per share. The dividend payout ratio stands at 50.19%. For the latest fiscal quarter, J&J reported revenue of $24.02 billion, net margin of 27.26% and return on equity of 32.73%. Analysts project full-year earnings per share of 10.58, supporting continued dividend growth from a current yield of 2.48% and underpinning the company’s 63-year streak of consecutive payout increases.